FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III
Freedom Broker analysts have maintained a "Buy" rating on aTyr Pharma (ATYR) shares with a $3.50 price target, suggesting a 536% upside from the current price. The key catalyst is the FDA's expected comments by the end of August on the protocol for a new Phase III study of efzofitimod for pulmonary sarcoidosis. Despite the potential, analysts note the investment remains high-risk, requiring a new Phase III trial and additional funding.
aTyr, Biogen, City name legal chiefs
Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels. These appointments reflect a focus on bolstering legal and compliance functions as these companies advance their therapeutic programs and expand their operations. The new legal chiefs bring extensive experience in the biopharmaceutical and biotechnology industries to their respective roles.
Why is aTyr Pharma stock gaining today?
aTyr Pharma's stock rose 1.8% in pre-open trading after announcing better-than-expected second-quarter results and a significant operational restructuring. The company reported a narrower loss per share, a 60% workforce reduction, and a focused pipeline on its lead candidate, efzofitimod, for interstitial lung disease. Investors are reacting positively to the extended cash runway, upcoming FDA feedback on a Phase 3 protocol, and completed enrollment in a Phase 2 study.
aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug
aTyr Pharma is laying off 60% of its workforce to conserve resources for a second attempt at phase 3 success for its lung disease drug, efzofitimod. The company is awaiting FDA feedback on a new phase 3 study protocol after the drug missed its primary endpoint in a previous trial. The restructuring is expected to save $13 million annually and extend the cash runway into late 2028, though additional capital will still be needed.
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) Investors - Contact Levi & Korsinsky Before December 8, 2025
Levi & Korsinsky LLP has issued a securities lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ:ATYR). The alert concerns a class action lawsuit filed against aTyr Pharma, Inc. seeking to recover losses for shareholders who were adversely affected by alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage, prior to a negative study announcement that caused a significant stock price drop.
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky
A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to help patients taper steroid usage. The stock price dropped significantly after the company announced its EFZO-FIT study did not meet its primary endpoint.
ATyr Pharma Announces Second Quarter 2026 Res
This article announces ATyr Pharma's second quarter 2026 results. The content is currently a placeholder and does not contain detailed financial information or a full report.
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma announced its second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program in interstitial lung disease (ILD). The company reduced its workforce by approximately 60% and is focusing resources on advancing efzofitimod, a novel biologic immunomodulator for ILD, in anticipation of FDA feedback on its planned Phase 3 study in pulmonary sarcoidosis. The restructuring is expected to reduce annualized operating expenses by about $13 million, extending the company's cash runway into late 2028.
aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary
aTyr Pharma (ATYR) reported a reduced net loss of $(10.3M) and an EPS of $(0.11) for Q2 2026, primarily due to lower research-and-development spending. The company plans to initiate a new global Phase 3 study for pulmonary sarcoidosis despite its EFZO-FIT trial missing its primary endpoint, and has implemented an operational restructuring including a 60% workforce reduction to conserve cash. aTyr Pharma is also advancing its preclinical candidate ATYR0101 and expanding its tRNA synthetase discovery platform.
aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD
aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash. The company is implementing a corporate restructuring, including a 60% workforce reduction, to conserve capital and focus on its lead candidate efzofitimod for interstitial lung disease (ILD). They have completed enrollment for a Phase 2 study in SSc-ILD and are awaiting FDA feedback on a Phase 3 protocol for pulmonary sarcoidosis.
ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus
aTyr Pharma Inc (NASDAQ: ATYR) announced its Q2 financial results and a major strategic restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung diseases. Despite an extremely high Price-to-Sales ratio of 255.7x and ongoing unprofitability, the company is preparing for FDA feedback on its Phase 3 pulmonary sarcoidosis study protocol. The stock is considered modestly overvalued by GuruFocus's GF Value™ and has a low GF Score™ of 18/100, though insider buying and stable guru ownership provide some positive signals.
aTyr Pharma cuts 60% of workforce after Q2 results
aTyr Pharma (ATYR) announced a 60% workforce reduction and corporate restructuring following its Q2 2026 results to prioritize its efzofitimod program. The company reported a net loss of $10.3 million and expects its current cash of $58.9 million to fund operations into late 2028. Key executive changes were also announced, with a planned Phase 3 study protocol submitted to the FDA and Phase 2 topline results expected in Q1 2027.
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky
A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) by Levi & Korsinsky, LLP, seeking to recover losses for shareholders who purchased stock between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod. The company's stock price dropped significantly after it announced that its EFZO-FIT study did not meet its primary endpoint on September 15, 2025.
aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD
aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash. The company is implementing a corporate restructuring, including a 60% workforce reduction, to conserve capital and focus on its lead candidate, efzofitimod, for interstitial lung disease (ILD). They have completed enrollment for their Phase 2 SSc-ILD study and are awaiting FDA feedback on a submitted Phase 3 protocol for pulmonary sarcoidosis, with topline results for the Phase 2 study expected in Q1 2027.
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma announced its second-quarter 2026 results and a corporate restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung disease (ILD). The company is awaiting FDA feedback by the end of August 2026 on its planned Phase 3 study protocol for pulmonary sarcoidosis and expects topline results from the Phase 2 EFZO-CONNECT™ study in SSc-ILD in the first quarter of 2027. This strategic shift aims to conserve capital and extend its cash runway into late 2028.
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma announced its second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program for interstitial lung disease (ILD). The company reduced its workforce by approximately 60% and enacted other cost-saving measures to focus resources on its lead asset, efzofitimod, as it awaits FDA feedback on a planned Phase 3 study in pulmonary sarcoidosis. Enrollment for the Phase 2 EFZO-CONNECT™ study in SSc-ILD is complete, with topline results expected in Q1 2027, and the company projects its cash reserves to last into late 2028.
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 - Contact Levi & Korsinsky
A class action securities lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage. The stock price dropped significantly after aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to an 83.2% decline in one day.
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans
ATyr Pharma reported a narrower fiscal Q2 loss. The company also announced restructuring plans, with further details provided in the last three paragraphs of the article. Access to the full MT Newswires article requires a premium subscription.
FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership
FMR LLC and Abigail P. Johnson have reported a 2.5% passive ownership stake in ATYR Pharma Inc. This disclosure, made via an amended Schedule 13G, indicates that FMR LLC beneficially owns 2,471,418 shares, with sole voting power over 2,464,141 shares and sole dispositive power over all 2,471,418 shares. Abigail P. Johnson also holds sole dispositive power over the same number of shares, reflecting her control over FMR-related entities.
Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025 – Contact Levi & Korsinsky
Levi & Korsinsky is alerting shareholders of aTyr Pharma, Inc. (ATYR) to protect their rights in a class action securities lawsuit. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to completely taper steroid usage. This led to a significant stock price decline after the EFZO-FIT study failed to meet its primary endpoint, resulting in an 83.2% drop in one day.
Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025 - Contact Levi & Korsinsky
Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod. The stock price dropped significantly after the company announced that a key study did not meet its primary endpoint, causing an 83.2% decline in one day.
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations – Contact Levi & Korsinsky Today
A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to reduce steroid usage. This news follows a significant 83.2% stock price drop on September 15, 2025, after aTyr announced its EFZO-FIT study did not meet its primary endpoint.
Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn
MarketScreener has withdrawn alerts regarding Ethos Technologies' Q2 results that were erroneously attributed to aTyr Pharma, Inc. The original publication was made on August 3, 2026, at 04:48 pm EDT by Reuters. This correction highlights a data misattribution concerning financial reporting.
aTyr Pharma Inc expected to post a loss of 12 cents a share - Earnings Preview
aTyr Pharma Inc is projected to report a loss of 12 cents per share, according to an earnings preview. This information is sourced from Refinitiv and was published by Reuters. The full article is available on TradingView, which aggregates news from various sources.
aTyr Pharma Inc (ATYR) Financial Health: Profitability & Balance Sheet Analysis
aTyr Pharma Inc (ATYR) currently holds a financial score of 6.87, ranking 190 out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. The report highlights that relevant financial data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company, making a comprehensive analysis challenging. The company's stock closed at $0.483, experiencing a -2.17% decrease.
ATYR|aTyr Pharma Inc|Price:0.499|Chg%:+0.010
This article presents a comprehensive stock analysis of aTyr Pharma Inc (ATYR) by TradingKey, highlighting its fundamental stability, high growth potential, and a fairly valued assessment within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows strong fundamentals and institutional confidence. Analysts have rated ATYR as a "Buy" with a significant upside potential, although the stock price is expected to trend down in the medium term.
aTyr Pharma Inc (ATYR) Institutional Confidence
The article details the institutional confidence score for aTyr Pharma Inc (ATYR), which is 5.00, placing it 132nd in the Biotechnology & Medical Research industry. It highlights a 24.02% quarter-over-quarter decrease in institutional shareholding proportion to 56.72%. The largest institutional shareholder is James Simons, holding 0.04% of shares outstanding, with a 3.15% decrease in holdings.
BlackRock (ATYR holder) reports 1.8% beneficial stake in aTYR PHARMA INC
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 1,725,072 shares of aTYR PHARMA INC (ATYR) common stock, which represents 1.8% of the class. BlackRock maintains sole voting and dispositive power over these shares. The filing clarifies that while various clients and funds benefit from these holdings, no single person's interest exceeds five percent of aTYR PHARMA's outstanding common shares, maintaining their stake below the 5% threshold for more stringent reporting.
aTyr Pharma Inc (ATYR) Cash Flow
This article provides a detailed historical cash flow statement for aTyr Pharma Inc (ATYR), covering quarterly and annual data from FY2013Q4 to FY2026Q1 across operating, investing, and financing activities. It also includes frequently asked questions defining key cash flow metrics and detailing ATYR's specific figures for operating, investing, and financing cash flows, as well as capital expenditures and free cash flow. The data highlights periods of both positive and negative cash flows, offering insights into the company's financial dynamics over more than a decade.
aTyr Pharma, Inc. Revenue Breakdown – NASDAQ:ATYR
aTyr Pharma, Inc. (NASDAQ: ATYR) generated $190,000 USD in revenue last year, primarily from its Efzofitimod segment. This figure is a decrease from $235,000 USD the previous year, with the United States being the sole contributor to both years' revenues. The article provides a brief overview of the company's revenue breakdown by segment and by country.
aTyr Pharma Ord Shs|Price:18.500|Chg%:-0.530
aTyr Pharma Ord Shs (LIFE) closed at $18.50, down 2.79%. The company shows strong fundamentals and high growth potential, despite a weak stock market performance over the past month. Analysts rate the stock as "Buy" with a target price of $28.00, suggesting a 47.14% upside.
LIFE stock trades quietly as aTyr Pharma focuses on R&D and recent loss narrows
aTyr Pharma Inc. (LIFE) is a clinical-stage biotechnology company focused on immune-modulating therapeutics. The company's latest annual results show lower revenue of $0.5 million but a narrowed net loss of $26.0 million, down from $30.0 million previously, indicating progress in cost management. Despite limited revenue, the company continues to invest heavily in its R&D pipeline, with a cash position of approximately $30.0 million supporting near-term operations.
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Hold Rating
H.C. Wainwright has reiterated its Hold rating for ATyr Pharma (ATYR.US). This indicates that the analyst firm recommends investors maintain their current position in the stock. The decision reflects the firm's current assessment of the company's financial outlook and market performance.
aTyr Pharma submits Phase 3 protocol for lung disease drug
aTyr Pharma (NASDAQ:ATYR) has submitted a Phase 3 study protocol to the FDA for its drug efzofitimod, targeting chronic pulmonary sarcoidosis with restrictive lung disease. This follows positive subgroup analysis from a previous Phase 3 study and the company expects to use forced vital capacity as the primary endpoint. Despite the drug's potential, InvestingPro highlights that aTyr Pharma is currently burning through cash, though it maintains a strong current ratio and more cash than debt.
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
aTyr Pharma will present a subgroup analysis of its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis at the WASOG 2026 Congress. The analysis shows that patients with restrictive lung disease treated with efzofitimod demonstrated clinically meaningful benefits in lung function and improvements in patient-reported outcomes. The company has submitted a protocol to the FDA for a planned Phase 3 study focusing on this specific patient population, utilizing FVC as the primary endpoint.
aTyr's 44-patient analysis shows 123.8 mL lung-function benefit
aTyr Pharma reported positive subgroup analysis from its Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis patients with restrictive lung disease. The 44 patients receiving 5.0 mg/kg efzofitimod showed a placebo-adjusted FVC benefit of 123.8 mL at week 48 and improvements in multiple patient-reported outcomes. The company has submitted a protocol to the FDA for a planned Phase 3 study focusing on this specific patient population using FVC as the primary endpoint.
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
aTyr Pharma will present a subgroup analysis of its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis at the WASOG 2026 Congress. The analysis focuses on patients with restrictive lung disease, showing clinically meaningful benefits in lung function and improvements in patient-reported outcomes with efzofitimod. The company recently submitted a protocol to the FDA for a planned Phase 3 study in this specific patient population.
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
aTyr Pharma announced it will present subgroup analysis data from its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis at the WASOG 2026 Congress. The analysis focuses on patients with restrictive lung disease, showing clinically meaningful benefits in lung function and patient-reported outcomes for those treated with 5.0 mg/kg efzofitimod. The company recently submitted a protocol to the FDA for a planned Phase 3 study for this specific patient population.
aTyr Pharma Inc (HAM:471A) Stock Price & 30 Year Financial Data
This article provides comprehensive 30-year financial data for aTyr Pharma Inc (HAM:471A), including growth rates for revenue, EPS, EBIT, EBITDA, and Free Cash Flow. It details the company's current market cap, enterprise value, and various financial ratios like P/E and P/B, alongside GuruFocus score. The data is presented with options for viewing annual and quarterly trends, customized fields, and export functionalities.
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating
JonesTrading has reiterated its Hold rating on ATyr Pharma (ATYR.US). This indicates that the firm advises investors to maintain their current position in the company's stock without recommending buying or selling.
Federated Hermes (NASDAQ: ATYR) amends 13G, reports 8.51M shares
Federated Hermes, Inc. has filed an amendment on Schedule 13G/A, disclosing beneficial ownership of 8,509,678 shares of aTYR PHARMA INC common stock, which represents 8.68% of the class as of June 30, 2026. The filing includes a Rule 13d-4 disclaimer, stating that Federated Hermes and related individuals disclaim beneficial ownership of securities held by managed funds. This update indicates a large passive stake by Federated Hermes, but no change in voting arrangements or transfers is implied.
aTyr Pharma, Inc. Actuals & Estimates (HAM:471A)
This article provides financial actuals and estimates for aTyr Pharma, Inc. (HAM:471A), including income statement, balance sheet, cash flow, and valuation metrics. It also offers analyst forecasts, historical price data, upcoming earnings reports, and key financial figures like EBITDA and net income. The company's stock ticker, analyst price targets, and details on buying shares are also covered.
aTyr Pharma updates its pipeline strategy as LIFE advances clinical programs
aTyr Pharma, a clinical-stage biotechnology company, is updating its pipeline strategy as its LIFE program and other protein-based therapeutic candidates progress through clinical development, targeting immune and inflammatory pathways. The company relies on equity financing, collaborations, and non-dilutive funding, with upcoming data readouts and regulatory interactions being key drivers for investor valuation. Headquartered in the US, aTyr Pharma's shares are sensitive to trial updates and financing decisions, impacting its high-risk, high-reward stock performance.
ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of aTyr Pharma, Inc. to Contact the Firm Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against aTyr Pharma, Inc. (NASDAQ:ATYR) on behalf of investors who purchased securities between January 16, 2025, and September 12, 2025. The lawsuit alleges that aTyr made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to help patients taper steroid usage. Investors who suffered losses are encouraged to contact the firm to discuss potentially becoming a lead plaintiff by the December 8, 2025 deadline.
If You Invested $1,000 in Atyr Pharma Inc (ATYR)
This article analyzes the historical performance of Atyr Pharma Inc (ATYR) stock, demonstrating the significant losses an investment of $1,000 would have incurred over 1, 5, and 10 years compared to the S&P 500. It also provides a detailed overview of Atyr Pharma, including its focus on tRNA synthetase biology, its lead therapeutic candidate efzofitimod for interstitial lung disease, and its broader clinical programs and discovery platform. Financial metrics and comparisons to similar stocks are included, alongside a summary of the company's public status and risks.
Enterprise value to EBIT forward of aTyr Pharma, Inc. – NASDAQ:ATYR
This article provides limited financial information for aTyr Pharma, Inc. (NASDAQ: ATYR) focusing on its enterprise value to EBIT forward. The content is primarily a data placeholder from TradingView, indicating that specific financial figures for this metric are not available or shown in the provided snippet. It also lists general information about TradingView's platform and data sources.
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities Violations - Contact Levi & Korsinsky Today
Levi & Korsinsky, LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims aTyr made misleading statements about the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage. This alleged deception led to an 83.2% stock price decline on September 15, 2025, after the company announced its EFZO-FIT study did not meet its primary endpoint.
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating
JonesTrading has reiterated its Hold rating for ATyr Pharma (ATYR.US). This indicates a neutral outlook on the company's stock performance from the analyst firm.
Price to book forward of aTyr Pharma, Inc. – NASDAQ:ATYR
This article provides access to the "Price to book forward" financial metric for aTyr Pharma, Inc. (NASDAQ: ATYR) on TradingView. It highlights that the market was closed at the time of access and offers no specific financial data within the provided text, instead serving as a portal to financial information.
Burned by aTyr Pharma, Inc.? Contact Levi & Korsinsky to SueWallSt And Fight Back
Levi & Korsinsky has filed a class action lawsuit against aTyr Pharma, Inc. on behalf of investors who experienced losses due to alleged securities fraud between November 7, 2024, and September 12, 2025. The firm, known for securing significant amounts for aggrieved shareholders, encourages affected investors to contact them for legal action. They also promote their SueWallSt podcast and WhatsApp channel for updates on class action news.
